



Tuberculosis Country Profile 2021 Singapore

Source: Global tuberculosis report 2021. Geneva: World Health Organization

Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.

Tuberculosis profile: Singapore

Population 2020: 5.9 million

Estimates of TB burden*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	2 700 (2 300-3 100)	46 (40-54)
HIV-positive TB incidence	27 (16-40)	0.46 (0.27-0.69)
HIV-negative TB mortality	25 (22-29)	0.43 (0.38-0.49)
HIV-positive TB mortality	5 (3-8)	0.08 (0.04-0.13)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2020	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	1% (1-1)

TB case notifications, 2020

Total new and relapse	2 357
- % tested with rapid diagnostics at time of diagnosis	94%
- % with known HIV status	91%
- % pulmonary	81%
- % bacteriologically confirmed [^]	60%
- % children aged 0-14 years	<1%
- % women (aged ≥15 years)	42%
- % men (aged ≥15 years)	58%
Total cases notified	2 362

TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	21	0.98%
- on antiretroviral therapy		

Drug-resistant TB care**, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	98%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	100%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	20
Patients started on treatment - MDR/RR-TB ^{^^^}	20
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	2
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	2
MDR/RR-TB cases tested for resistance to any fluoroquinolone	12

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	79%	2 072
Previously treated cases, excluding relapse, registered in 2019	100%	5
HIV-positive TB cases registered in 2019	91%	33
MDR/RR-TB cases started on second-line treatment in 2018	47%	15
XDR-TB cases started on second-line treatment in 2018		0

TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	84% (62-100)

TB financing


National TB budget, 2021 (US\$ millions)	17
--	----

* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
 ** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
[^] Calculated for pulmonary cases only
^{^^} Includes cases with unknown previous TB treatment history
^{^^^} Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed


Incidence, New and relapse TB cases notified, HIV-positive TB incidence



HIV-negative TB mortality



Incidence, Notified cases by age group and sex, 2020



Cases attributable to five risk factors, 2020

